Literature DB >> 6717888

Lonidamine plus adriamycin versus adriamycin alone in the adjuvant treatment of recurrent papillary carcinomas of the urinary bladder.

P Giannotti, F Ambrogi, G B Ciottoli.   

Abstract

This paper reports the interim results of 25 patients included in a double-blind study in which the combination of Lonidamine plus adriamycin is compared to adriamycin alone in the adjuvant treatment of papillary carcinomas of the urinary bladder. Although it is impossible to draw any conclusion at this time on the therapeutic activity of this combination, tolerance was judged satisfactory.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6717888     DOI: 10.1159/000225896

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  3 in total

1.  Relative cytotoxicities of adriamycin and epirubicin in combination with lonidamine against human bladder cancer cell lines.

Authors:  R J Popert; J R Masters; M Coptcoat; G Zupi
Journal:  Urol Res       Date:  1995

2.  Phase II study of lonidamine in metastatic breast cancer.

Authors:  P Pronzato; D Amoroso; G Bertelli; P F Conte; M P Cusimano; G B Ciottoli; M Gulisano; R Lionetto; R Rosso
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640

3.  A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer.

Authors:  J L Mansi; A de Graeff; D R Newell; J Glaholm; D Button; M O Leach; G Payne; I E Smith
Journal:  Br J Cancer       Date:  1991-09       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.